Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Effect of ivarmacitinib on swelling and tenderness in small and large joints and imaging changes in patients with moderate-to-severe RA: a post hoc analysis of a phase III clinical trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04333771 (A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.
Who cites it
2 citing papers in PubMed.
- Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety.Drug design, development and therapy · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This post hoc analysis of a phase III clinical trial (NCT04333771) was aimed at evaluating the effect of ivarmacitinib (SHR0302) on joint symptoms in small and large joints and imaging changes in patients with moderate-to-severe rheumatoid arthritis (RA). Patients were randomized to receive 24-week ivarmacitinib 4 mg (n = 189), ivarmacitinib 8 mg (n = 189), or placebo (n = 188). At week (W) 24, patients receiving placebo switched to ivarmacitinib 4 mg; others continued initial regimens until W52. Changes in swollen joint count (SJC) and tender joint count (TJC) in small and large joints from baseline, and imaging changes from baseline to W24, were evaluated. Compared with the placebo group, ivarmacitinib 4 mg and 8 mg groups demonstrated greater reductions in SJC and TJC in small and large joints over the initial 24 weeks and showed sustained improvement throughout the treatment. Ivarmacitinib 4 mg and 8 mg groups showed greater reductions in TJC in small joints versus large joints at several time points, with especially pronounced effects in the ivarmacitinib 8 mg group from W20 to W52. From W24 to W52, patients switched to ivarmacitinib 4 mg exhibited sufficient improvement in SJC and TJC of small and large joints, with greater reductions in TJC in small joints versus large joints. Ivarmacitinib 4 mg and 8 mg groups showed greater reductions in bone erosion and synovitis scores under MRI scanning from baseline to W24 versus the placebo group. Ivarmacitinib improves swelling and tenderness in small and large joints in patients with moderate-to-severe RA, with superior effects on tenderness in small joints.
Indexed as
Identifiers
41741728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.